Large studies, mostly based on series of patients receiving CSA/tacrolimus (TKR) plus MTX as immunoprophylaxis, have demonstrated a deleterious effect on survival of the presence of a single mismatch out of eight loci after allogeneic hematopoietic SCT (alloHSCT). We retrospectively analyzed a series of 159 adult patients who received sirolimus(SRL)/TKR prophylaxis after alloHSCT. We compared overall outcomes according to HLA compatibility in A, B, C and DRB1 loci at the allele level: 7/8 (n = 20) vs 8/8 (n = 139). Donor type was unrelated in 95% vs 70% among 7/8 vs 8/8 pairs, respectively (P = 0.01). No significant differences were observed in 3-year OS (68 vs 62%), 3-year EFS (53 vs 49%) and 1-year non-relapse mortality (9 vs 13%). Cumulative incidence of grades II-IV acute GVHD (aGVHD) was significantly higher in 7/8 alloHSCT (68% vs 42%, P o0.001) but no significant differences were found for III-IV aGVHD (4.5% vs 11%), overall (35% vs 53%) and extensive (20% vs 35%) chronic GHVD in 7/8 vs 8/8 subgroups, respectively. In summary, the present study indicates favorable outcomes after alloHSCT using the combination of SRL/TKR combination as GVHD prophylaxis with OS in the range of 55-70%, and non-significant differences in overall outcomes, irrespective of the presence of any mismatches at obligatory loci.
INTRODUCTION
The degree of high-resolution HLA matching at A, B, C and DRB1 loci strongly influences overall outcomes after allogeneic hematopoietic SCT (alloHSCT). [1] [2] [3] [4] In fact, as described by Lee et al., 1 in patients with early or intermediate disease status undergoing transplantation, OS decreases by around 10% for each additional mismatch at an Ag and/or allelic position. These findings come mainly from studies including large numbers of patients receiving GVHD prophylaxis with a calcineurin inhibitor (CSA or tacrolimus (TKR)) plus MTX or micophenolate (MMF), usually with myeloablative conditioning. However, our knowledge regarding the impact of HLA mismatch on post-transplant outcomes using other immunosuppressive combinations are more limited, although several studies have reported that in vivo T-cell depletion with anti-thymocyte globulin (ATG) can overcome the deleterious effect of HLA mismatch. [5] [6] [7] [8] [9] [10] Unfortunately, this approach might hamper the GVL effect and increase the risk of infectious complications. 11 Promising results have been reported using the combination of TKR and sirolimus (TKR-SRL) after reduced-intensity conditioning (RIC) allogeneic transplantation from unrelated donors (URD). [12] [13] [14] [15] [16] [17] A recent trial by the GETH (Grupo Español de Trasplante Hematopoyético) found a significantly higher OS (70 vs 45% at 2 years) and lower non-relapse mortality (NRM) (18 vs 38% at 2 years) using TKR-SRL rather than CSA-MMF. A significant reduction in the incidence of chronic GVHD (cGVHD) was also observed with TKR-SRL. 17 Against this background, the current study aimed to analyze overall outcomes with respect to the presence or absence of mismatches at any HLA locus involving A, B, C and DRB1 in a series of patients undergoing RIC alloHSCT and who had received TKR-SRL as immunoprophylaxis.
PATIENTS AND METHODS Patients
Fifty patients receiving alloRIC and GVHD prophylaxis with TKR-SRL were recruited in a previous prospective trial (2007-006416-32 GEL-TAMO/GETH trial). 17 This strategy was subsequently used as the standard approach to prevent GVHD in the RIC setting in 109 additional patients from six institutions. Finally, 159 patients were evaluated in the current study. Patients received transplants between February 2007 and September 2012. The study was approved by the Ethics Committees of each center, and each patient provided written, informed consent after a detailed explanation, in accordance with the Declaration of Helsinki.
HLA compatibility was studied by high-resolution typing for obligatory loci A, B, C and DRB1, and for DQB1. Detailed information about mismatch locations was provided for the whole group.
The conditioning regimen, GVHD prophylaxis and supportive carehave been fully described elsewhere. 17 Briefly, patients received a conditioning regimen based on fludarabine plus melphalan or BU (for lymphoid or myeloid malignancies, respectively), and 19 patients received thiotepa (10 mg/kg total dose) plus fludarabine (150 mg/m 2 ) and BU (9.6 mg/kg). Immunoprophylaxis was based on SRL at 6 mg qd p.o. on day − 6, followed by 4 mg qd p.o. from day − 5, plus TKR started on day − 3 at a dose of 0.02 mg/kg/day as a continuous i.v. infusion. Doses of both drugs were adjusted to target blood levels within 5-10 ng/mL for each. In the absence of acute GVHD (aGVHD), TKR was reduced by 5% per week, starting on day +56 and stopped on day +180, whereas SRL was reduced from day +180, stopping on day +240. Antiviral, antibacterial and antifungal prophylaxis was performed according to each institution's standard practice.
Definitions
Disease status at transplant was categorized as early (first CR for acute leukemias, untreated myelodysplastic syndrome with fewer than 10% blasts in BM aspirate), intermediate (4first CR) or advanced (PR, active or refractory disease and prior transplant).
Post-transplant complications, such as aGVHD and cGVHD, venoocclusive disease and thrombotic microangiopathy, were defined and graded according to established criteria. [18] [19] [20] [21] Grade 3-4 organ toxicities were graded according to the Common Terminology Criteria for Adverse Events Version 4 (http://www.eortc.be/services/doc/ctc/CTCAE). Severe infections caused by CMV and proven and probable invasive fungal infections (based on EORTC criteria) were also reported. Abbreviations: ATG = anti-thymocyte globulin; HD = Hodgkin disease; LR = serological testing for A,B or low-resolution PCR testing; MDS = myelodysplastic syndrome; MM = multiple myeloma; MMF = mycophenolate mofetil; NHL = non-Hodgkin lymphoma; NRM = non-related relapse mortality; PCR-HR = DNA high-resolution HLA testing, to the allele level. *Advanced disease as defined in the main text: second or further CR, PR, active or refractory disease, and/or previous autologous or allogeneic transplant.
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Statistical analysis
The primary outcomes considered were the cumulative incidence of aGVHD (overall and grades 3-4), overall and extensive cGVHD, NRM, relapse rate, OS and EFS, comparing these between 7/8 HLA-matched pairs and 8/8 matched pairs. aGVHD, cGVHD, NRM and relapse were analyzed and compared using the Gray test. 23 The cumulative incidence was computed with the cmprsk package for R 2.14.0 software (R Development Core Team (2011); http://www.R-project.org/). Competing events were defined as follows. For aGVHD or cGVHD and relapse the competing event was death without occurrence of the event of interest. Relapse was considered the competing event for NRM and GVHD. OS and EFS were estimated by the Kaplan-Meier method, and groups were compared with the log-rank test.
Events were calculated from the time of transplantation as follows. NRM was defined as death from any cause (GHVD-related or other cause), without prior relapse or progression of the underlying disease. Relapse incidence was analyzed from transplant until the time of relapse in those patients in remission before or after transplant. EFS was calculated from transplant until disease progression or death, and those patients who did not achieve a disease response (CR or PR) any time after transplant were considered events on day 100, because this was the earliest date for complete disease evaluation. OS was calculated from transplant until death from any cause, and surviving patients were censored at their final followup. Patients who showed evidence of engraftment could be evaluated for aGVHD, whereas those who engrafted and survived more than 100 days could be evaluated for cGVHD. For aGVHD and cGVHD, the day of onset was analyzed as the time to event in evaluable patients.
Associations of patients and disease characteristics with the main outcomes were evaluated in multivariate Cox proportional hazard models. The influence of aGVHD and cGVHD was evaluated by treating the occurrence of GVHD as a time-dependent variable that switched from 0 to 1 when the event occurred after transplantation. Multivariate Cox regression was performed to control the effects of HLA mismatching and other variables such as age, sex, basal disease and status at transplant. Because the type of donor was co-linear with HLA mismatching, it was not included in the multivariate analysis. The proportional hazards assumption was tested analytically and graphically for each variable.
Differences were considered to be statistically significant for two-sided values of Po 0.05. Confidence intervals (95%) were also calculated. Except where otherwise stated, all analyses were carried out using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics are summarized in Table 1 , comparing two subgroups of patients based on 7/8 (n = 20) vs 8/8 HLA compatibility (n = 139). There were no statistically significant differences between the two subgroups except for donor type (URD in 95% patients with 7/8 vs 69.6% among 8/8, P = 0.01) and stem cell source (PB in 98% vs 70.4% in 7/8 vs 8/8, respectively, P o0.001).
A DQB1 mismatch was present in nine patients receiving URD transplant, four of whom were included in the 7/8 subgroup (i.e., 8/10 matched), and the remaining five in the 8/8 subgroup.
Hematological recovery and GVHD No significant differences were found with respect to neutrophil and platelet engraftment between the two groups. Only two cases of primary graft failure were reported, both in the 8/8 subgroup (one patient died after cord blood transplant and the other one successfully underwent a second allogeneic transplant from the same donor, and he is alive at last follow-up).
In 7/8 recipients, the onset of aGVHD was significantly earlier (30 vs 71 days, P = 0.02) and the cumulative incidence of II-IV aGVHD was significantly higher, with respect to 8/8 patients (68% (95% confidence interval (CI) = 49.5-94.5) vs 41% (95% CI = 32.5-51)) at 100 days, P o0.001, Figure 1a) , and mainly grade II (70.5% of cases; Table 2 ). However, there were no significant differences in terms of grade III-IV aGVHD (4.5% (95% CI = 0.6-32) vs 11% (95% CI = 7-18), P = 0.3), overall cGVHD (35% (95% CI = 19-66) vs 53% (95% CI = 44-64) at 1 year, and 66% (95% CI = 46-95) vs 79.6% (95% CI = 69-91) at 3 years, P = 0.3, Figure 1b ) and extensive cGVHD (20%, 95% CI = 8-49 vs 35%, 95% CI = 26.0-45.5 at 1 year and 48%,95% CI = 28-83 vs 53%, 95% CI = 42-66% at 3 years, P = 0.6) in 7/8 vs 8/8, respectively. Of the patients who developed aGVHD, there was a 100% CR rate with first-line therapy with steroids for 7/8 patients (15/15) and 71% in 8/8 patients (P = 0.1). Multivariate analysis identified HLA mismatch as the only variable that significantly increased the risk of aGVHD (hazard ratio (HR) = 2.7, 95% CI = 1.6-4.8, P = 0.001).
No significant differences were found in other post-transplant complications between the groups, such as CMV and proven or probable invasive fungal infections, veno-occlusive disease, thrombotic microangiopathy and 3-4 organ toxicities (Table 1) .
Overall outcomes With a median follow-up of 21.5 months (6-53) for patients alive at last follow-up, a trend towards a higher relapse risk was found in 7/8 patients (1-year cumulative incidence: 38%, 95%CI = 21-67 vs 14%, 95% CI = 9-22 in 8/8 subgroup, P = 0.1). In multivariate analysis for relapse, the donor type was the only significant risk factor (sibling donor decreased the risk of relapse with a HR: 0.3 (0.1-0.8), P = 0.01). Just a trend was found with respect to presence of mismatched (7/8 vs 8/8, with a HR = 2.4, 95% CI = 0.8-5.6, P = 0.08). Neither II-IV acute nor chronic extensive GVHD significantly influenced on relapse. There were no significant differences in overall outcomes between the two groups with respect to NRM (9%, 95% CI = 2.0-35.5 vs 13%, 95% CI = 8.5-21.0 at 1 year, P = 0.2, Figure 2 ), OS (77.09 vs 79.5% at 1 year and 68.0 vs 62.0% at 3 years, P = 0.8, Figure 3a) and EFS (53 vs 72% at 1 year and 53 vs 49%, at 3 years, P = 0.5, Figure 3b ) in 7/8 vs 8/8 patients, respectively.
In multivariate analysis, the variables that significantly influenced NRM were: diagnosis of AML or myelodysplastic syndrome vs others (HR = 0.1, 95% CI = 0.02-0.50, P = 0.008) and grade II-IV aGVHD (HR = 3.8, 95% CI = 1.3-10.7, P = 0.009). Regarding OS, grade II-IV GVHD was the only variable that significantly influenced on outcome (HR = 2.6, 95% CI = 1.3-5.4, P = 0.007). (20) 2 (20) Abbreviation: NR = non-response. Eight out of 11 patients with GVHD refractory to first-line therapy finally died, whereas two out the three remaining patients were alive at last follow-up (one of them with a moderated chronic GVHD, both in CR of basal disease) and the other one died because of disease relapse. Adapted from Przepiorka et al.
a
Two out of 10 (20%) patients with a PR of acute GHVD were refractory to subsequent lines and finally died. Four patients (40%) developed chronic GVHD and one of them died because of a lethal infection in the setting of non-responding chronic extensive GVHD (at +248 days from transplant). The four remaining patients finally responded and all but one were alive in CR at last follow-up. Sirolimus-tacrolimus in mismatched allogeneic transplantDISCUSSION The impact of one or more mismatches at obligatory HLA loci on overall outcomes after transplant has been extensively analyzed in the setting of unrelated donor HSCT. OS decreases by approximately 10% for each additional mismatch. 1 This deleterious effect persists in both myeloablative and non-myeloablative HSCT, whereas among patients with advanced disease status outcomes are poor, irrespective of the presence or absence of HLA mismatches, ranging from 17 to 10% at 5 years for those receiving transplantation from HLA matched versus mismatched donors. [1] [2] [3] [4] 24 However, these findings mainly come from a series of patients receiving immunoprophylaxis with a calcineurin inhibitor plus MTX, whereas the impact of HLA mismatch using other strategies has not been extensively analyzed. The impact of HLA mismatch on outcomes might differ with the type of GVHD prophylaxis used, and information from one approach cannot necessarily be extrapolated to other strategies. In this regard, Finke et al. 25 reported similar outcomes in a series of 100 patients irrespective of the presence (n = 25) of HLA mismatch when ATG was added to CSA and MTX as GVHD prophylaxis. This approach yielded no differences either in terms of aGVHD and cGVHD or mortality, and only disease status at the time of transplant influenced survival after alloHSCT. More recently, a multicenter randomized study with Fresenius ATG (103 vs 98 patients) also showed that the degree of mismatch (n = 31 in the ATG group) did not have a significant impact on aGVHD and cGVHD in patients receiving ATG. 26 Lee et al. 10 reached a similar conclusion in the setting of RIC including ATG. Scarce literature has been published about the addition of ATG to TKR and SRL. Al-Kadhimi et al. 27 reported on a series of 47 unrelated alloHSCT, including 25 7/8 pairs. The cumulative incidences of grade II-IV aGVHD and cGVHD were 23.4% and 33%, respectively; the 2-year cumulative incidence of NRM was 31.9% and 1-year PFS was 54%. However, a recent phase II trial with 32 patients receiving the same regimen of ATG (4.5 mg/kg total dose) plus SRL and TKR had to be curtailed because of a high incidence of graft failure (12.5%). 28 On the other hand, Shaw et al. 29 described a heterogeneous group of 423 transplants in which the presence of one mismatch at the DPB1 level significantly reduced the risk of relapse, which in turn improved the survival of patients at high risk of relapse at the time of transplant. Finally, regarding the use of ATG, several studies have reported a positive effect on the incidence of cGVHD and, consequently, a better quality of life post transplant. [7] [8] [9] 30 For this reason, it is commonly used in patients receiving transplantation from unrelated mismatched donors. However, it is not clear whether T-cell depletion procedures confer advantages on overall outcomes, because the decreased risk of aGVHD and cGVHD may be counterbalanced by a potentially greater risk of relapse, graft failure and development of opportunistic infections. 11 In this regard, other strategies avoiding in vivo or ex vivo T-cell depletion would be desirable. However, studies comparing T-cell depletion to the combination of rapamycin plus TKR are lacking.
In the last decade, several studies have reported promising results using the combination of TKR plus SRL as immunoprophylaxis in the setting of reduced-intensity alloSCT.
12-14,31-33 For example, Dana Farber's group described that similar outcomes could be obtained by this approach using related or unrelated donor transplants. 14, 32 However, as far as we know, no studies have analyzed the effect of HLA mismatch on overall outcomes using TKR-SRL. In our previous study, 17 we found a positive outcome in the setting of alloRIC URD transplants among patients receiving TKR-SRL, which compared favorably to those obtained using CSA plus MMF in terms of OS (72 vs 48%, P = 0.01), risk of overall GVHD (55 vs 88%, P o 0.001) and extensive cGVHD, as well as a significant reduction of NRM (1-year NRM: 19 vs 40%, P = 0.02). Armand et al. 34 recently reported on a series of 139 patients with lymphoma undergoing alloHSCT and compared overall outcomes between TKR-SRL plus MTX and others (TKR-MTX or CSA-MMF), finding a significant reduction in grade 2-4 aGVHD (9 vs 25%, P = 0.01), with no significant differences in OS (66 vs 71% in TKR-SRL plus MTX vs TKR plus MTX or CSA-MMF, respectively) and NRM (14% for both groups, similar to the value for our study of patients receiving TKR-SRL). By contrast, our control group had significantly worse outcomes, which could be because, in our series, only patients undergoing unrelated donor transplants were included in the study and because the control group was exclusively based on CSA-MMF. 17 In the current study, there is a notably and unexpectedly high OS (over 70% at 1 year) for the whole group, regardless of the presence of mismatch, and a low NRM (less than 15% at 1 year), especially given the predominance of advanced disease status at the time of transplant for 73% of patients. These data are consistent with those of previous studies by Cutler et al., [32] [33] [34] most of which involved non-myeloablative regimens, in which 1-year EFS and OS were 71% and 67%, respectively. More intensive conditioning strategies have been avoided because of the potential higher risk of veno-occlusive disease with the TRK-SRL combination. 35 However, promising data have been published with TKR-SRL and CY-TBI, 14 reporting a 1-year EFS and OS of 72% and 77%, respectively.
Finally, in spite of a higher risk of grade 2-4 aGVHD in 7/8 patients, it is worth mentioning that, in the current study, the risk of severe aGVHD was not significantly different in 7/8 compared with 8/8 patients and that the percentage of patients achieving CR after first-line treatment for aGVHD with steroids was very high, thus confirming that most of the differences in terms of aGVHD were not related to severe forms of aGVHD. Moreover, mortality was low in both subgroups (9 and 13% at 1 year).
In conclusion, the present study is the first to analyze the effect of mismatch on overall outcomes after alloSCT with TKR-SRL, and shows unexpectedly promising results in terms of OS and NRM, even in patients with advanced disease. Considering the similar overall outcomes found in 7/8 and 8/8 patients, the use of TKR-SRL seems to overcome the deleterious effect of mismatch at obligatory loci. However, larger series of patients are required to confirm these results.
